Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Jiangxi Rimag Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jiangxi-rimag-group-co-ltd" target="_blank" data-smartkarma-citation="entities:39800:1" rel="noopener">Jiangxi Rimag Group (2522 HK)</a> is placing 35M shares for subscription at HK$16.76 per share.</li>
<li>The company intends to use the net proceeds to further strengthen their data service capabilities using AI, business expansion through independent investments or acquisitions, and general corporate purpose.</li>
<li>In the medium to long term the company is well-positioned for sustainable growth with its relentless pursuit for new investments, collaborations, and acquisitions.</li>
</ul>



Jiangxi Rimag Group (2522 HK) is placing 35M shares for subscription at HK$16.76 per share.
The company intends to use the net proceeds to further strengthen their data service capabilities using AI, business expansion through independent investments or acquisitions, and general corporate purpose.
In the medium to long term the company is well-positioned for sustainable growth with its relentless pursuit for new investments, collaborations, and acquisitions.


Rimag Group (2522 HK): Placement Seem Conducive Given The Prospects